Related Experiment Video

Updated: Aug 10, 2026

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Brief report: Therapeutic benefit of ISA-2011B in colorectal cancer

Veroniaina Hanitrarimalala1,2, Jenny Persson1,2,3, Anette Gjörloff Wingren4,5,6

  • 1Department of Biomedical Sciences, Faculty of Health and Society, Malmö University, Malmö, Sweden.

Molecular Biology Reports
|August 8, 2026
PubMed

Insights

The drug ISA-2011B shows varied effects on colorectal cancer (CRC) cell lines, suggesting potential as a targeted therapy. Mutations in KRAS and PI3K genes influence treatment outcomes for this promising CRC drug candidate.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Phosphatidylinositol-4-phosphate 5-kinase-α (PIP5K1α) inhibitors are explored for cancer therapy.
  • ISA-2011B is a selective PIP5K1α inhibitor with reported efficacy in prostate, breast, and hepatic cancers.

Purpose of the Study:

  • To evaluate the efficacy of ISA-2011B in colorectal cancer (CRC) cell lines.
  • To assess the impact of different mutations on ISA-2011B treatment response in CRC.

Main Methods:

  • Investigated cell viability of four CRC cell lines using 2D cultures and 3D spheroids.
  • Performed imaging and measured average volumes of 3D spheroids after ISA-2011B treatment.

Main Results:

  • ISA-2011B demonstrated differential effects across the four CRC cell lines.
  • Mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS) and phosphatidylinositol 3-kinase (PI3K) genes correlated with treatment outcomes.

Conclusions:

  • ISA-2011B exhibits potential as a therapeutic agent for colorectal cancer.
  • Further research is warranted to explore ISA-2011B as a drug target in CRC, considering genetic mutations.
Keywords:
3D spheroidsColorectal cancerISA-2011BPIP5K1αViability

More Related Videos

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma07:59

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Published on: September 3, 2021

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...